Prognosis of<unk> s is given in relation to what grade (as scored by the World Health Organization system) of tumour the patient presents with. Typically, any tumour presenting as above WHO grade I (i.e. a malignant tumour as opposed to a benign tumour) will have a prognosis resulting in eventual death, varying from years (WHO grade II/III) to months (WHO grade IV). Prognosis can also be given based on cellular subtype, which may also impact prognosis. Low grade For low-grade tumors, the prognosis is somewhat more optimistic. Patients diagnosed with a low-grade<unk>  are 17 times as likely to die as matched patients in the general population. The age-standardized 10-year relative survival rate was 47%. One study reported that low-grade oligodendroglioma patients have a median survival of 11.6 years; another reported a median survival of 16.7 years. Unfortunately, approximately 70% of low-grade (WHO grade-II) will progress to high-grade tumours within 5–10 years High grade This group comprises anaplastic astrocytomas and<unk> oblastoma multiforme. Whereas the median overall survival of anaplastic (WHO grade III)<unk> s is approximately 3 years,<unk> oblastoma multiforme has a poor median overall survival of c. 15 months. Postoperative conventional daily radiotherapy improves survival for adults with good functional well‐being and high grade<unk>  compared to no postoperative radiotherapy. Hypofractionated radiation therapy has similar efficacy for survival as compared to conventional radiotherapy, particularly for individuals aged 60 and older with<unk> oblastoma. Diffuse intrinsic pontine<unk>  Diffuse intrinsic pontine<unk>  primarily affects children, usually between the ages of 5 and 7. The median survival time with DIPG is under 12 months. Surgery to attempt tumour removal is usually not possible or advisable for DIPG. By their very nature, these tumours invade diffusely throughout the brain stem, growing between normal nerve cells. Aggressive surgery would cause severe damage to neural structures vital for arm and leg movement, eye movement, swallowing, breathing, and even consciousness. Trials of drug candidates have been unsuccessful. The disease is primarily treated with radiation therapy alone. IDH1 and IDH2-mutated<unk>  Patients with<unk>  carrying mutations in either IDH1 or IDH2 have a relatively favorable survival, compared with patients with<unk>  with wild-type IDH1/2 genes. In WHO grade III<unk> , IDH1/2-mutated<unk>  have a median prognosis of ~3.5 years, whereas IDH1/2 wild-type<unk>  perform poor with a median overall survival of c. 1.5 years. In<unk> oblastoma, the difference is larger. There, IDH1/2 wild-type<unk> oblastoma have a median overall survival of 1 year, whereas IDH1/2-mutated<unk> oblastoma have a median overall survival of more than 3 years.
Glioma
Gliosis
Glioblastoma
Astrocytoma
Meningioma
Malignant meningioma
Ameloblastoma
Coma